NEW YORK (GenomeWeb) – Eisai subsidiary Morphotek today announced a collaboration and licensing agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.